Literature DB >> 24843963

[Efficacy observation on benign prostatic hyperplasia treated with acupuncture and moxibustion].

Ze-Jie Xu.   

Abstract

OBJECTIVE: To compare the difference in the clinical efficacy on benign prostatic hyperplasia (BPH) between the acupuncture-moxibustion therapy and the medication of Qianliekang tablets.
METHODS: One hundred and twenty-eight patients were randomized into an acupuncture-moxibustion group and a Qianliekang group, 64 cases in each one. In the acupuncture-moxibustion group, acupuncture was applied to Shenshu (BL 23), Pangguangshu (BL 28), Zhongji (CV 3), Guanyuan (CV 4) and Shuidao (ST 28), and the warm moxibustion therapy with moxa stick was used at Shenshu (BL 23), Guanyuan (CV 4) and Shenque (CV 8), once every day. In the Qianliekang group, Qianliekang tablets were prescribed for oral administration, 4 tablets each time, three times a day, for 3 months. The International Prostate Symptom Score (I-PSS) and the changes in residual urine (Ru) and maximal urine flow rate (Qmax) determined with the ultrasonic B test were compared before and after treatment in the two groups.
RESULTS: The results of I-PSS, Qmax and Ru were improved obviously after treatment as compared with those before treatment in the two groups (all P < 0.05). The improvements in the acupuncture-moxibustion group were much more obvious than those in the Qianliekang group [8.62 +/- 2.18 vs 15.26 +/- 2.81, (16.04 +/- 4.33) mL/s vs (12.47 +/- 2.13) mL/s, (10.43 +/- 2.14) mL vs (32.13 +/- 3.24) mL, all P < 0.01]. The total effective rate was 89.1% (57/64) in the acupuncture-moxibustion group, which was better than 68.7% (44/64) in the Qianliekang group.
CONCLUSION: Acupuncture-moxibustion therapy achieves the significant efficacy on BPH, which is better than the oral administration of Qianliekang tablets.

Entities:  

Mesh:

Year:  2014        PMID: 24843963

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  5 in total

1.  The effect of Qianliekang tablets on the clinical efficacy, immune function, and inflammatory factor levels in the prostatic fluid of elderly chronic prostatitis patients.

Authors:  Chao Yang; Jun Yao; Tianping Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Acupuncture for benign prostatic hyperplasia: a systematic review protocol.

Authors:  Wei Zhang; Jinna Yu; Zhishun Liu; Weina Peng
Journal:  BMJ Open       Date:  2015-04-02       Impact factor: 2.692

3.  Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.

Authors:  Hye-Yoon Lee; Jong-Kil Nam; Sang-Don Lee; Dong-Hoon Lee; Ji-Yeon Han; Young-Ju Yun; Ji-Hye Lee; Hye-Lim Park; Seong-Ha Park; Jung-Nam Kwon
Journal:  BMJ Open       Date:  2015-12-11       Impact factor: 2.692

4.  Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial.

Authors:  Hye-Yoon Lee; Go-Eun Bae; Sang-Don Lee; Jong-Kil Nam; Young-Ju Yun; Ji-Yeon Han; Dong-Hoon Lee; Jun-Young Choi; Seong-Ha Park; Jung-Nam Kwon
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

5.  Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial.

Authors:  Hyo Bin Kim; Young Il Kim; Ju Hyun Jeon; Eunseok Kim; Jin Youp Kim; Ojin Kwon; Young Eun Choi; Changsop Yang; Chang-Hyun Han
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.